aTYR PHARMA INC
ATYR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ATYR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ATYR
aTYR PHARMA INC (ATYR) is a clinical-stage biotech developing efzofitimod for pulmonary sarcoidosis, with no product revenue and a history of operating losses.
Key risk: No product revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$53.0M
Cash Runway
17.8 moLead Asset
ATYR0101 (Preclinical)
Next Catalyst
Phase2_Topline · Mar 31, 2027Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 1 clinical trial · 1 catalyst for aTYR PHARMA INC.
aTYR PHARMA INC (ATYR) is a clinical-stage biotech developing efzofitimod for pulmonary sarcoidosis, with no product revenue and a history of operating losses.
- Lead candidate efzofitimod targets pulmonary sarcoidosis, a major interstitial lung disease, and has completed a Phase 3 EFZO-FIT study with an FDA Type C meeting held in May 2026 [news].
- Cash, equivalents, restricted cash, and investments totaled $58.9 million as of June 30, 2026, with an accumulated deficit of $627.3 million [sec_mda · as of 2026-08-07].
- Net loss for the six months ended June 30, 2026 was $10.3 million, and operating cash used was $21.9 million [sec_mda · as of 2026-08-07].
- The company has no product sales revenue and expects to need substantial additional funding to continue operations and advance efzofitimod [sec_mda · as of 2026-05-15].
- aTYR has a 98%-owned Hong Kong subsidiary, Pangu BioPharma, and is exploring other tRNA synthetase-based immunomodulators [sec_mda · as of 2026-08-07].
What works
- Efzofitimod has advanced to a Phase 3 study and received FDA feedback, indicating regulatory engagement and potential for a defined path forward [news · published 2026-05-11].
- The company's approach targeting FGFR4 with ATYR0750 is described as differentiated from other approaches, which may offer a unique therapeutic benefit [sec_mda · as of 2026-05-15].
- aTYR has raised significant capital through equity offerings, including $66.4 million from an ATM program in 2025, demonstrating ongoing access to public markets [sec_mda · as of 2026-08-07].
What to weigh
- The company has never generated product revenue and has an accumulated deficit of $627.3 million as of June 30, 2026, with continued net losses expected [sec_mda · as of 2026-08-07].
- Cash and investments of $58.9 million as of June 30, 2026 may be insufficient to complete the planned Phase 3 study for efzofitimod without additional funding [sec_mda · as of 2026-05-15].
- The company announced a restructuring plan in 2026, which may involve charges and uncertainties that could impact operations [sec_mda · as of 2026-08-07].
- Clinical development timelines and costs are inherently unpredictable, and the probability of success for efzofitimod remains uncertain [sec_mda · as of 2026-05-15].
From the filings
Quoted directly from source documents.
Accumulated deficit reached $627.3 million as of June 30, 2026.
“As of June 30, 2026, we had an accumulated deficit of $627.3 million, and we expect to continue to incur net losses for the foreseeable future.”
SEC MD&A · August 7, 2026
Cash and investments totaled $58.9 million as of June 30, 2026.
“As of June 30, 2026, we had cash, cash equivalents, restricted cash and available-for-sale investments of $58.9 million.”
SEC MD&A · August 7, 2026
No revenue from product sales to date.
“To date, we have not derived any revenue from product sales.”
SEC filings · March 26, 2026
Catalyst timeline
- 2027-03-31 · Phase2_Topline · efzofitimod — Phase 2 Readout: efzofitimod — Top-line data from the Phase 2 study of efzofitimod in pulmonary sarcoidosis will be a key value inflection point.
Risks & what to watch (4)›
Key risks
- No product revenue — The company has never generated product sales revenue and relies entirely on external financing [sec · filed 2026-03-26].
- Cash runway uncertainty — Cash of $58.9M as of June 30, 2026 may not be sufficient to complete the planned Phase 3 study without additional capital [sec_mda · as of 2026-08-07].
- Clinical development risk — Efzofitimod's Phase 3 results and regulatory path are uncertain; timelines and costs can differ materially from expectations [sec_mda · as of 2026-05-15].
- Restructuring execution — The 2026 restructuring plan may incur charges and disrupt operations, with actual outcomes subject to assumptions [sec_mda · as of 2026-08-07].
What to watch
- Top-line results from the Phase 2 study of efzofitimod expected around March 31, 2027 [catalyst].
- Cash burn rate and any new equity or partnership financing to extend runway beyond current $58.9M [sec_mda · as of 2026-08-07].
- FDA feedback and next steps for efzofitimod following the Type C meeting in May 2026 [news · published 2026-05-11].
- Progress of ATYR0750 and other tRNA synthetase-based programs in preclinical or early clinical stages [sec_mda · as of 2026-05-15].
Sources: News · SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run aTYR PHARMA INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available aTYR PHARMA INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
17.8 months
D/E 0.43 · 0% dilution
Lead: Phase 3
3 candidates
1 upcoming, next in ~213d
1 buy · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
112
Total value held
$43.2M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 14,706,843 | $11.5M |
| federated hermes, inc. | 10,509,678 | $8.2M |
| vanguard capital management llc | 7,624,264 | $5.9M |
| blackrock, inc. | 6,443,904 | $5.0M |
| geode capital management, llc | 2,385,485 | $1.9M |
| state street corp | 1,754,399 | $1.4M |
| millennium management llc | 1,641,246 | $1.3M |
| morgan stanley | 1,225,467 | $956K |
| two sigma investments, lp | 1,144,565 | $893K |
| susquehanna international group, llp | 1,132,344 | $883K |
Showing top 10 of 112 institutional holders of aTYR PHARMA INC. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 23.3%
- Days to cover
- 22.0
- Shares short
- 19,845,053
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ATYR short interestGovernance
Frequently asked questions
What is the AI investment thesis for aTYR PHARMA INC?
aTYR PHARMA INC (ATYR) is a clinical-stage biotech developing efzofitimod for pulmonary sarcoidosis, with no product revenue and a history of operating losses.
What is aTYR PHARMA INC's lead drug candidate?
aTYR PHARMA INC's most advanced tracked candidate is ATYR0101 (Preclinical) for Fibrotic diseases (pulmonary fibrosis, SSc, liver fibrosis and kidney fibrosis).
What is aTYR PHARMA INC's next catalyst?
aTYR PHARMA INC's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: efzofitimod" — expected March 31, 2027.
Who is the CEO of aTYR PHARMA INC?
Dr. Sanjay S. Shukla M.D., M.S. is the chief executive officer of aTYR PHARMA INC (ATYR).
Where is aTYR PHARMA INC headquartered?
aTYR PHARMA INC (ATYR) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.